The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...
The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...
SCOTTSDALE, Ariz., Aug. 5, 2025 /PRNewswire/ -- Amendola, a nationally recognized, award-winning healthcare technology and life sciences public relations and marketing firm, announced ArcheHealth has...
Milan, Italy – August 5, 2025 – Tensive S.r.l, a clinical-stage advanced biomaterials medical device company, and the developer of REGENERA™ and SOFTAG™ bioresorbable scaffolds for breast reconstruction and tissue marking, has appointed Bill Hunter, MD, as Chairman of its Board of Directors. Dr. Hunter brings more than 30 years of leadership in the medical technology and life sciences sectors. His appointment reflects Tensive’s focus on strengthening its governance and expanding its global network as it accelerates toward pivotal clinical milestones and commercialization in the U.S. and Europe.
Company intends to use the net proceeds from this financing primarily to rapidly increase its ETH holdings
Company plans to execute a differentiated yield generation...
BEIJING, China, Aug. 4, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the successful completion of its RMB...
The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...
The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...
DURHAM, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it issued grants of employment inducement awards to Anshul Thakral, the Company’s recently appointed President and Chief Executive Officer, as an inducement material to Mr. Thakral becoming a new employee of the Company. The grants were previously approved by the independent members of the Company’s Board of Directors and were made in connection with Mr. Thakral’s start date with the Company on August 4, 2025 (the “Effective Date”).
The digital therapeutics market is anticipated to increase due to the growing global burden of chronic conditions such as diabetes, cardiovascular disorders, and obesity...
The digital therapeutics market is anticipated to increase due to the growing global burden of chronic conditions such as diabetes, cardiovascular disorders, and obesity...